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STREAM
The practical stream is a series of concurrent sessions that are designed to be mare interactive, hands 0n style sessi}ns. The topics covered in
this stream are designed for atrlied health staff such as educators, nurses, social workers, dietitians and also general paediatricians.
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Turner syndrome (TS) and related sex chromosome
abnormalities are associated with a variety of karyotypes
and phenotypes affecting 1 in 2500 live births, Mosaicism
with Y material (45,X46,XY) and female phenotype is rare
(<1 in 15 000 births)(1). Their risk of gonadal malignancy
is 10-15%, and up to 50% in those with ambiguous
phenotype at birth(2). The SHOX gene is located on both
X and Y chromosomes but is more prone to deletions on
the X chromosome, potentially influencing height outcomes
across TS karyotypes(3). However, children with SHOX
deficiency respond similarly to TS girls when treated with
the same dose of growth hormone (GHX4). We therefore
examined height outcomes and gonadal malignancy rates in
TS vs 45,)V46,XY females.
We identified 198 females aged < 30 years with TS or mixed
gonadal dysgenesis treated with GH (underTS or auxological
criteria). Final height (FH) was available on 51 TS (45,X or
mosaic without Y material) females. An additional 13 had
45,X146,XY karyotype with TS phenotype, and two had non-
mosaic 46,XY karyotypes with cytogenetic abnormalities
consistent with TS. Of these 15 females, gonadal tissue
histology was available for 11 and FH in nine. We evaluated
patient records for age, height, mid-parental height (MPH),
GH dose at commencement, duration of therapy and growth
response at 12 months and at FH. Comparisons between
TS and 45,W46,XY groups were performed using the Mann-
Whitney U test.
All 45,X46,XY patients had a female phenotype and five
had clitoromegaly at birth. Three were identified prenatally;
age at diagnosis ranged from birth to 13 years, with the
most common presenting features being short stature (n=5),
ambiguous genitalia (n=5) and dysmorphic features (n=2).
Of the 11 that underwent gonadectomy, four (none virilised at
birth) had a gonadoblastoma, including one dysgerminoma
in situ.
Age, height, MPH,GH dose at commencement, duration
of therapy and height z-score afler' 12 months did not
differ between groups. Median FH z-score for 45,X46,XY
was higher than TS, -1.12 [range ;1.96,0.31], vs -1.59
[-3.12,0.01], P=0.016. Response to GH therapy (median A
height z-score) after 12 months was similar: 0.45 [-0.04,0.84]
vs 0.39 l-0.21 ,1.141, p=a.61 . However, height response over
the total duration of therapy was better for 45,X46XY: 1.5
10.72,2.881 vs 0.87 [-0.e8,2. 1 4], p=0.009.
45,W46,XY females appear to respond differently to GH
therapy, suggesting a possible contribution ol SHOX on
the Y chromosome. The rate of germ cell tumours in non-
virilised females (36%) is higher than previously reported.
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Aims: Mutations in Steroidogenic Acute Regulatory protein
(SIAR) cause congenital lipoid adrenal hyperplasia (lipoirl
CAH), characterized by absent steroidogenesis, potentially
lethal salt loss, 46,XY sex reversal and massively enlarged
adrenals engorged with cholesterol esters. Nonclassic lipoid
CAH is a recently recognized disorder caused by SA FI
mutations that retain partial function. We aim to delineate
the clinical and mutational spectrum of SiAR mutations in
patients with lipoid CAH.
Methods: The entire coding regions of the SIAF gene were
assessed by polymerase chain reaclion and sequencing
analysis.
Results: There were 10 patients of lipoid CAH had mutations
in the SIAR gene with 5 novel mutations (p.P230b!{fsX,
lVS6-1G>A, lVS3+(2-3)insT, p.W147R, p.Q264R). EiSht
patients had classic lipoid CAH presenting with adrenalcrisis
during early infancy (range of onset 3-11 months ol age).
Two siblings had nonclassic phenotypes with later onset
adrenal insufficiency without disordered sex development.
Adrenal enlargement by imaging was demonstrated in only
3 cases of classic lipoid CAH. The functional studies of novel
SIAR mutations are being under investigation.
Conclusion: SIAF mutations may not be rare in Southeast
Asian population. There is a broad clinical spectrum of StAF
mutations varying from early onset adrenal insufficiency to
late onset of glucocorticoid deficiency with only mild defects
in mineralocorticoid and sex steroid synthesis. Adrenal
gland enlargement is not pathognomonic for lipoid CAH.
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ln lndonesia clinical management ol DSD is challenged
by limited knowledge and limited diagnostic and treatment
facilities. Prior to this study, most patients remained
unlreated and grew up with ambiguous bodies and doubts
about their gender. We investigated patients'experiences of
being raised in ambiguity.
ll8lndonesian patients, ages 6-41, with 46XX DSD (n=27),
46XY DSD (n=77) and chromosomat DSD (n=14) were
compared to 118 control subjects matched for gendel age,
and living area. Questionnaires for gender identity, gender
role behavior and social stigmatization were translated or
designed. The psychometric properties were satisfactory.
For patient and control group comparisons, Mann-Whitney
U and Fisher's Exact tests were applied.
The results showed thal 7"k of the children, g% of the
adolescents and 44y" of the adults changed gender,
particularly non-diagnosed and non-treated patients with
zl6XY DSD (81ol.). 95% of the patients changed gender
from female to male, including untreated patients with
46)0( CAH-SV. Compared to control groups, cross_gender
role behavior was seen in young girls with 46XX CAH-SV
(F.044 ard adolescent girls with different types of DSD
(F.01). ln girls with DSD, conf usion with gender identity was
seen (young girls p=.994; adolescent girts p=.01). Aduti men
repgded past cross-gender role behavior (p=.01) and past
problems in gender identilication (p=.01) prior to female-to_
male gender change.
ChiHren with genital ambiguity (p<.006) and cross gender
behavior (p<0.001) and adults with ambiguous bodies
(p=.001) and adutts who changed gender (p<b.OS) suffered
stigmatization. Rejection or isolation elicited depression and
withdrawalfrom social activities in girls (p=.002) and women
(p=.009) and youngsters who had changed genler (p=.02).
We contyde that high percentage of our patiehb chhnged
gende.r. The wjsh for gender change was'particularty sEen
in patients with progressive masculinizatidn. patienis with
DSD who had visible ambiguity in physical and behavioral
appearance suffered stigmatization. Teasing and rejection
led.to strong emotional reactions. Early clin'ical evaiuation
and. treatment, patierrt and parent eduiation, and teaching
coping strategies will improve quality of life.
